1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow danicopan: new trials by email Literature Review of danicopan trials Research Report on danicopan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis Danicopan - Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 6 | 2025-08-11 | 2025-12-23 |
| A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH Danicopan - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 80 | 2022-10-28 | 2026-06-18 |
| Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) Danicopan, Placebo, C5 Inhibitor - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 86 | 2020-12-16 | 2025-05-04 |
Hemoglobinuria, Paroxysmal (3) · Hemolysis (3)
Alexion Pharmaceuticals, Inc. (3)
Canada (3) · France (3) · United Kingdom (3) · Brazil (2) · Czechia (2) · Greece (2) · Israel (2) · Italy (2) · Japan (2) · Malaysia (2) · Poland (2) · South Korea (2) · Spain (2) · Thailand (2) · United States (2)
2019 (1)